Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?

Frontiers in Oncology

Oncology

Mark van Duin¹  Carolina Terragna²  Mattia D’Agostino³ 

[1] Department of Haematology, Erasmus Medical Center, Rotterdam, Netherlands;IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy;SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy;

关键词: multiple myeloma;    prognosis;    risk assessment;    minimal residual disease;    liquid biopsy;   

DOI  :  10.3389/fonc.2023.1247808

 received in 2023-06-26, accepted in 2023-07-21,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 D’Agostino, Terragna and van Duin